Sign in
Taking people in United StatesPhase 2

CRD-4730 for adults with catecholaminergic polymorphic ventricular tachycardia

Tests CRD-4730 against placebo in adults with catecholaminergic polymorphic ventricular tachycardia.

Key facts

Who runs it
Cardurion Pharmaceuticals, Inc.
Where
Houston, Madison, Morrisville, Salt Lake City, and San Francisco, United StatesSee the 5 sitesAlso in 5 other countries, 7 sites
Registry title
A Phase 2 Study of CRD-4730 in CPVT
Status
Recruiting
Phase
Phase 2
People taking part
12 people, planned
Started
1 Dec 2025
Expected to end
Apr 2027
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • CRD-4730
  • Placebo
Record updated
9 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with CPVT, an inherited heart rhythm disorder, caused by a harmful RYR2 gene change. It tests CRD-4730 against a placebo (a dummy tablet).

Age
18 Years to 99 Years, and of legal adult age where you live
Sex
Men and women
Disease stage
Confirmed CPVT with signs that fit the disease. During an exercise stress test, the doctor must see frequent extra heartbeats (PVCs; ≥10 per minute), ventricular bigeminy, or more serious irregular rhythms (VA score ≥2).
Earlier treatment
Stable dose of at least 1 heart rhythm medicine (beta blockers count, amiodarone does not) for 4 weeks before screening, unless these medicines were not tolerated before. No extra heart rhythm drugs beyond the usual regimen, unless at least 5 half-lives have passed.
Biomarker or test result
A disease-causing mutation in the RYR2 (ryanodine receptor) gene, shown by genetic testing.

Main reasons for not taking part

  • Significant structural heart disease, heart failure or coronary artery disease, or an abnormal ECG such as prolonged QT
  • Heart attack, stroke or mini-stroke, ICD implant, or sympathetic nerve denervation within 3 months of screening
  • Cancer within the past 5 years (some skin and cervical cancers excepted), or any past chest radiation
  • Hepatitis B, hepatitis C or HIV infection, or liver problems shown in blood tests
  • Pregnant, breastfeeding, or planning pregnancy during the study or within 3 months after the last dose

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Each participant must meet all the following criteria to be enrolled in this study:
  • The participant is male or female, ≥18 years of age and of legal adult age in accordance with local requirements
  • The participant has a confirmed CPVT diagnosis, based on genetic screening for a pathogenic ryanodine receptor (RYR2) mutation and a clinical phenotype consistent with CPVT at Screening. Previous CPVT genetic testing documented in medical history is acceptable if confirmed by the Investigator and documented in the study source records
  • The participant can perform an EST during which frequent premature ventricular contractions (PVCs; ≥10 per minute), ventricular bigeminy, or higher-grade VA (equivalent to a VA score ≥2) are identified by the Investigator
  • The participant has been on a stable dose of at least 1 antiarrhythmic medication (including beta blockers but not amiodarone) for 4 weeks prior to Screening, unless the participant has been unable to tolerate antiarrhythmic therapy previously
  • Adheres to all contraceptive criteria

Who cannot take part

  • The female participant is pregnant, lactating/breastfeeding, or has plans to become pregnant during the study or within 3 months following the last study drug administration
  • The participant has taken any antiarrhythmic drug in addition to their stable, chronic regimen unless it has been at least 5 half-lives since administration at the time of Screening
  • The participant has clinically significant structural heart disease, diagnosis of heart failure, or clinically significant coronary artery disease
  • The participant has a history of a myocardial infarction, cerebrovascular accident, or transient ischemic attack within 3 months of Screening
  • The participant has a history of malignancy within the past 5 years at Screening, with the exception of successfully treated basal cell carcinoma or nonmetastatic squamous cell carcinoma of the skin or cervical carcinoma in situ. Prior exposure to chest radiation for any malignancy is exclusionary
  • The participant has abnormal blood pressure, defined as supine symptomatic hypotension, systolic blood pressure >150 mm Hg or diastolic blood pressure >90 mm Hg, or symptomatic bradycardia or a heart rate >100 bpm at Screening and/or on Day 1. Blood pressure and pulse should be measured after the participant has been in the seated position after 5 minutes of rest
  • The participant has acute or chronic hepatitis B (HBV; defined as hepatitis B surface antigen [HBsAg] reactive), acute or chronic hepatitis C virus (HCV; defined as detection of HCV antibody and RNA [qualitative]), or human immunodeficiency virus (HIV) infection
  • The participant has a clinically significant abnormal ECG not explained by the diagnosis of CPVT at Screening or clinically significant abnormal intervals, such as prolonged QT
  • The participant has hepatic impairment defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 × (upper limit of normal [ULN]) and/or total bilirubin >1.5 × ULN at Screening (unless secondary to confirmed Gilbert syndrome)
  • Participants meeting any of the following criteria will be excluded from the study:
  • The participant undergoes implantable cardioverter-defibrillator (ICD) implantation or has sympathetic nerve denervation within 3 months of Screening
  • The participant has an anticipated change in exercise regimen or new exercise program during the course of the study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 99 years old?

Where in United States

Also in 5 other countries, 7 sites

  • Houston, TexasHospital not named in the registryContact: CardurionTaking people
  • Madison, WisconsinHospital not named in the registryContact: CardurionTaking people
  • Morrisville, North CarolinaHospital not named in the registryContact: CardurionTaking people
  • Salt Lake City, UtahHospital not named in the registryContact: CardurionTaking people
  • San Francisco, CaliforniaHospital not named in the registryContact: CardurionTaking people

About the trial

What the trial wants to find out

This is a Phase 2, multicenter, double-blind, sponsor blinded, placebo-controlled, repeat-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 to participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). Participants with CPVT will complete a 3-period, randomized 3-sequence study. Each participant will be randomized to one of the 3 sequences in which they will receive 2 different doses of CRD-4730 and 1 dose of matching placebo.

The 3 groups in the trial

  • Dose 1Treatment being tested

    CRD-4730 Dose 1 Tablet

    Treatment: CRD-4730

  • Dose 2Treatment being tested

    CRD 4730 Dose 2 Tablet

    Treatment: CRD-4730

  • Dose 3Placebo, for comparison

    Placebo tablet to match CRD-4730

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 2, Double-Blind, Repeat-Dose, Placebo-Controlled Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CRD-4730 In Participants With Catecholaminergic Polymorphic Ventricular Tachycardia
Plain-language title
CRD-4730 for adults with catecholaminergic polymorphic ventricular tachycardiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT06658899, who can take part
Record updated
9 July 2026